Oppenheimer Raises Target on Cubist Pharmaceuticals (CBST) On Advancing Pipeline, Cubicin Growth Trajectory
Tweet Send to a FriendGet Alerts CBST Hot Sheet
Price: $49.51 +1.81%
Rating Summary:
9 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
9 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade CBST Now!
Oppenheimer lifted its price target on Outperform-rated Cubist Pharmaceuticals (NASDAQ: CBST) from $49 to $55.
The firm comments, "We are increasing our price target on shares of CBST from $49 to $55, on a maturing late-stage pipeline and better than expected Cubicin sales growth trajectory. Specifically, we take this opportunity to add revenue from OIC candidate, CB-5945, to our estimates beginning in 2016, which results in an additional $4/share in valuation. Separately, based on script data, Cubicin sales are trending ahead of our expectations for 3Q12. We believe it is likely that management raises 2012 Cubicin sales guidance on the 3Q12 conference call on 10/18 (dial-in: (855) 319-7654, pw: 13972921). Since the longer-term Cubicin sales trajectory appears ahead of our prior estimates, we increase our sales estimates and estimation of value for Cubicin."
For an analyst ratings summary and ratings history on Cubist Pharmaceuticals click here. For more ratings news on Cubist Pharmaceuticals click here.
Shares of Cubist Pharmaceuticals closed at $46.99 yesterday, with a 52 week range of $34.58-$49.86.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm comments, "We are increasing our price target on shares of CBST from $49 to $55, on a maturing late-stage pipeline and better than expected Cubicin sales growth trajectory. Specifically, we take this opportunity to add revenue from OIC candidate, CB-5945, to our estimates beginning in 2016, which results in an additional $4/share in valuation. Separately, based on script data, Cubicin sales are trending ahead of our expectations for 3Q12. We believe it is likely that management raises 2012 Cubicin sales guidance on the 3Q12 conference call on 10/18 (dial-in: (855) 319-7654, pw: 13972921). Since the longer-term Cubicin sales trajectory appears ahead of our prior estimates, we increase our sales estimates and estimation of value for Cubicin."
For an analyst ratings summary and ratings history on Cubist Pharmaceuticals click here. For more ratings news on Cubist Pharmaceuticals click here.
Shares of Cubist Pharmaceuticals closed at $46.99 yesterday, with a 52 week range of $34.58-$49.86.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- UBS Survey Shows Signs of Strength for Gilead's (GILD) TAF
- Goldman Sachs Describes Cisco (CSCO) Q3 as 'Breakout Performance'
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
